Gsk Share Discussion Threads

[philanderer] 17/10/2017 09:30

17th oct Goldman Sachs buy -

reiterates

[philanderer] 16/10/2017 20:41

16th oct Jefferies buy tp 1700p up from 1650p


'GlaxoSmithKline launches consumer sensory lab in UK'

[tradermichael] 14/10/2017 08:20

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older.[i] Shingrix is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses.

Shingles is caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox.[ii] A person's risk for shingles increases sharply after 50 years of age. Nearly all adults over 50 have the shingles virus dormant in their nervous system, waiting to reactivate with advancing age. Up to one in three Canadians will develop shingles in their lifetime.[iii](,[iv],[v])

"One of the biggest challenges in vaccine research is to create vaccines that are effective in older adults who are at greater risk for certain diseases, like shingles. As we age, our immune system loses the ability to mount a strong and effective response to infection[vi]. Shingrix was developed specifically to overcome the age-related decline in immunity against the varicella zoster virus," said Dr Thomas Breuer, Senior Vice President and Chief Medical Officer of GSK Vaccines.

Shingrix is the first shingles vaccine to combine a non-live antigen, to trigger a targeted immune response, with a specifically designed adjuvant to generate a strong and sustained immune response.

[essentialinvestor] 12/10/2017 12:17

Forgot it was payment day )

[tradermichael] 12/10/2017 11:16

Wish I could say the same. I mean, I have some fat dividend payments coming in, but I shouldn't think I'll see them for 5 days. You see, I've been transferred from Barclays Stockbrokers to Barclays Smart Investor. Everything seems to take at least 5 days with Barclays online banking. (Except for the fees, that is - and they are higher). Won't be too long before I set up new accounts with AJ Bell ...... ;0)

[philanderer] 12/10/2017 09:44

Nice dividend paid into the account this morning :-)

[zho] 11/10/2017 10:43

Is GlaxoSmithKline the worst-governed company in the FTSE 100 index? Can Barclays really be the fourth best?

The Institute of Directors thinks so – or, rather, its Good Governance Report has produced these rankings for 2017 based on 47 “indicators” of good governance weighted according to significance. It all sounds terribly objective and mathematical until you examine the breakdown of the scores and realise nobody applied a filter for common sense....

[tradermichael] 10/10/2017 14:48

I remember that Pfizer bought a number of consumer lines from GSK some years back.

[alphorn] 10/10/2017 14:34

Pfizer weighs sale of consumer health business - I am sure that they are not alone?

[tradermichael] 10/10/2017 13:20

A GSK spokesperson said: “We take our responsibilities with regard to corporate governance very seriously, particularly in areas such as executive pay, board governance, employee diversity, audit management and relations with external stakeholders. While there is always more we could do, we don’t recognise the conclusions of this work and will seek to understand the findings fully.”

[philanderer] 10/10/2017 09:58

'GlaxoSmithKline ranked worst in business group's list of well run companies in the UK'

Drinks giant Diageo topped the Institute of Director's ranking for good governance

[cool druid] 08/10/2017 12:50

[...]

Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS)
By Alliance | Fri, 6th October 2017 - 14:19

LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company.
The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin.
Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo.
The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%.
Merrill Lynch had a holding that was below the notable threshold prior to the purchase.
Motif Bio shares were up 6% on Friday at 46.11 pence.
By Joshua Warner; [e-mail]; @JoshAlliance

Read more:

A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure.
Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment

[ny boy] 06/10/2017 14:47

Can't see it, going to 1550p as snow initial target then above 1600p

[mj19] 06/10/2017 12:42

Sold today held from 1450 good luck all but I think finished it's wave 5 and we need to do down to lower low

[ny boy] 05/10/2017 16:07

City chappy..one of the reasons why I have been accumulating IMM since early 50p's!

Here, plodding up nicely, divi payout next Thursday, will keep the missus happy.

[philanderer] 05/10/2017 10:24

Liberum defends ‘beaten up’ GlaxoSmithKline


Shares in GlaxoSmithKline (GSK) have been beaten up for no good reason, according to Liberum, which believes the outlook for the pharmaceutical giant is better than the market expects.

Analyst Roger Franklin retained his ‘buy’ recommendation but lowered the target price from £19.00 to £17.60. The shares fell 9p to £15.11 yesterday.

‘GlaxoSmithKline is off c.10% versus EU pharma, in dollars, since the end of May, despite stronger fundamentals including benign competitor data in HIV, a quality beat at the second quarter, upgraded pharma margin guidance and the confirmed dividend,’ he said.

He believes concerns about the pricing of respiratory drugs and the company’s research and development (R&D) programme ‘have unfairly weighed on the shares’.

‘Instead we believe the earnings outlook is better than consensus expects and there is 16% upside to fair value if Glaxo can deliver just breakeven R&D over the longer term, in line with its historical performance,’ said Franklin.

[city chappy] 04/10/2017 09:02

I think GSK need to look at buying IMM's Lupus drug Lupuzor that finishes Phase III in Q1 2018 and seems to be better than GSK's Benlysta on efficacy and tolerability. It certainly seems set to make IMM or who ever buys it a lot of money.

[philanderer] 04/10/2017 08:53

4th oct Liberum buy tp 1760p cut from 1900p

[ny boy] 03/10/2017 10:58

Onwards & upwards, decent buying, just got to cheap.

1550p, first resistance level, that is the initial target

[toffeeman] 03/10/2017 10:42

Ironhorse I sincerely hope and expect that your petition fails to garner sufficient support and even if it does, then our elected representatives will consign it to the dustbin of history.

Two wrongs do not make a right.

[ny boy] 02/10/2017 22:32

Monty you still short? 😄